Cargando…

Novel cytokine–antibody fusion protein, N-820, to enhance the functions of ex vivo expanded natural killer cells against Burkitt lymphoma

BACKGROUND: The prognosis of patients with relapsed or progressive B cell (CD20(+)) non-Hodgkin’s lymphoma (B-NHL), including Burkitt lymphoma (BL), is dismal due to chemoradiotherapy resistance. Novel therapeutic strategies are urgently needed. N-820 is a fusion protein of N-803 (formerly known as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chu, Yaya, Nayyar, Gaurav, Kham Su, Nang, Rosenblum, Jeremy M, Soon-Shiong, Patrick, Lee, John, Safrit, Jeffrey T, Barth, Matthew, Lee, Dean, Cairo, Mitchell S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592258/ https://www.ncbi.nlm.nih.gov/pubmed/33109629 http://dx.doi.org/10.1136/jitc-2020-001238

Ejemplares similares

Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2(+) pediatric solid tumors and in vivo survival of xenografted immunodeficient NSG mice
por: Chu, Yaya, et al.
Publicado: (2021)

Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors
por: Razak, Albiruni RA, et al.
Publicado: (2020)

TEM8 Tri-specific Killer Engager binds both tumor and tumor stroma to specifically engage natural killer cell anti-tumor activity
por: Kaminski, Michael F, et al.
Publicado: (2022)

PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations
por: Fabian, Kellsye P, et al.
Publicado: (2020)

Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells
por: Pietà, Anna Dalla, et al.
Publicado: (2021)

Individualized genetic makeup that controls natural killer cell function influences the efficacy of isatuximab immunotherapy in patients with multiple myeloma
por: Sun, Haibo, et al.
Publicado: (2021)

Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition
por: Crist, McKenzie, et al.
Publicado: (2022)

Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody
por: Park, Jeong A, et al.
Publicado: (2023)

Initiation of immunotherapy with activated natural killer cells and anti-GD2 antibody dinutuximab prior to resection of primary neuroblastoma prolongs survival in mice
por: Zobel, Michael John, et al.
Publicado: (2020)

Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)
por: Bilusic, Marijo, et al.
Publicado: (2021)

Investigation of the prognostic value of CD4 T cell subsets expanded from tumor-infiltrating lymphocytes of colorectal cancer liver metastases
por: Kroemer, Marie, et al.
Publicado: (2020)

Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve
por: Fabian, Kellsye P, et al.
Publicado: (2021)

Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors
por: Natoli, Marina, et al.
Publicado: (2022)

Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy
por: Reimann, Hannah, et al.
Publicado: (2021)

IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)
por: Pachynski, Russell K, et al.
Publicado: (2021)

Intratumor expanded T cell clones can be non-sentinel lymph node derived in breast cancer revealed by single-cell immune profiling
por: Jiao, Shiping, et al.
Publicado: (2022)

Intratumoral IFN-γ or topical TLR7 agonist promotes infiltration of melanoma metastases by T lymphocytes expanded in the blood after cancer vaccine
por: Tran, Christine A, et al.
Publicado: (2023)

Atezolizumab in patients with renal insufficiency and mixed variant histology: analyses from an expanded access program in platinum-treated locally advanced or metastatic urothelial carcinoma
por: Hoffman-Censits, Jean, et al.
Publicado: (2020)

INBRX-120, a CD8α-targeted detuned IL-2 that selectively expands and activates tumoricidal effector cells for safe and durable in vivo responses
por: Sulzmaier, Florian J, et al.
Publicado: (2023)

Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors
por: Nayyar, Gaurav, et al.
Publicado: (2019)

Risk-adapted chemoimmunotherapy using brentuximab vedotin and rituximab in children, adolescents, and young adults with newly diagnosed Hodgkin’s lymphoma: a phase II, non-randomized controlled trial
por: Hochberg, Jessica, et al.
Publicado: (2022)

High endothelial venule is a surrogate biomarker for T-cell inflamed tumor microenvironment and prognosis in gastric cancer
por: Park, Hyung Soon, et al.
Publicado: (2021)

Clinical outcomes of prexasertib monotherapy in recurrent BRCA wild-type high-grade serous ovarian cancer involve innate and adaptive immune responses
por: Lampert, Erika J, et al.
Publicado: (2020)

Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma
por: Lee, Pei-Chang, et al.
Publicado: (2020)

Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor–treated unresectable hepatocellular carcinoma
por: Lee, Pei-Chang, et al.
Publicado: (2022)

Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity
por: Hong, Tae Hee, et al.
Publicado: (2020)

Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D
por: Park, Junsik, et al.
Publicado: (2023)

First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors
por: Leidner, Rom, et al.
Publicado: (2023)

Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer
por: Pyo, Kyoung-Ho, et al.
Publicado: (2020)

Antibody profiling of patients with prostate cancer reveals differences in antibody signatures among disease stages
por: Potluri, Hemanth K, et al.
Publicado: (2020)

Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade
por: Jeong, Seongju, et al.
Publicado: (2021)

FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy
por: Choueiri, Toni K, et al.
Publicado: (2022)

Tumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy
por: Buchwald, Zachary S, et al.
Publicado: (2020)

Rapid corticosteroid taper versus standard of care for immune checkpoint inhibitor induced nephritis: a single-center retrospective cohort study
por: Lee, Meghan D, et al.
Publicado: (2021)

Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors
por: Desai, Jayesh, et al.
Publicado: (2020)

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
por: Tarhini, Ahmad A, et al.
Publicado: (2021)

Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages
por: Ou, Da-Liang, et al.
Publicado: (2021)

In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis
por: Kim, Seohyun, et al.
Publicado: (2021)

Human CD141(+) dendritic cells (cDC1) are impaired in patients with advanced melanoma but can be targeted to enhance anti-PD-1 in a humanized mouse model
por: Lee, Yoke Seng, et al.
Publicado: (2021)

Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer
por: Naqash, Abdul Rafeh, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_00qnt2dnnjbum3n9728j780scv